Loading…
5 companies · GEL, thousands · columns ordered by revenue
GEL, thousands · money Σ · ratios from summed bases · growth on the pooled series
| Metric | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2,420 | 25,327 | 31,916 | 39,410 | 41,218 | 20,886 | 22,953 | 12,937 |
| EBITDA | 301 | 2,012 | 2,931 | 3,841 | 2,714 | 3,282 | 2,272 | 642 |
| Net profit | 4,538 | 1,616 | 2,501 | 2,745 | 2,313 | 2,541 | 1,483 | 281 |
| Total assets | 10,942 | 11,690 | 13,621 | 19,349 | 21,773 | 12,828 | 16,213 | 3,664 |
| n (companies reporting) | 5 | 5 | 5 | 5 | 5 | 3 | 3 | 2 |
GEL, thousands
| Company | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 |
|---|---|---|---|---|---|---|---|---|
| Parmaneti | 0 | 2,978 | 4,402 | 4,836 | 5,677 | 4,719 | 5,284 | 6,688 |
| GNG Pharma | 2,420 | 3,622 | 4,767 | 6,282 | 6,152 | 7,443 | 6,737 | 6,249 |
| Akhali Khedva | 0 | 3,168 | 4,344 | 5,807 | 7,150 | 8,724 | 10,932 | — |
| Iberi + | 0 | 10,389 | 12,333 | 15,398 | 14,992 | — | — | — |
| Iberiparma + | 0 | 5,169 | 6,072 | 7,087 | 7,246 | — | — | — |
Rows are the raw pool — every peer, including any excluded from the sums above, so the de-duplication stays auditable. Tinted cells are the excluded company-years.
Peer coverage varies by year — FY2017, FY2022–FY2024 pool fewer than the 5 picked companies (see the n row). A year is never dropped because one peer is missing.
Pooled figures sum every peer in the set. Known parent/subsidiary groups that file separately are de-duplicated; groups not yet curated may still be counted more than once.